Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Blood‐based genes and co‐expression network levels are associated with AD/MCI diagnosis, cognitive, and neuroimaging phenotypes and preserved in the brain
Chen, Xuan, Wang, Xue, Reddy, Joseph S. , Quicksall, Zachary , Nguyen, Thuy T. , Reyes, Denise Alexandra Chavez, Lowe, Val J. , Petersen, Ronald, Kantarci, Kejal, Nho, Kwangsik, Allen, Mariet , Carrasquillo, Minerva M., Saykin, Andrew Joel, Ertekin‐Taner, Nilüfer, Petersen, Ronald, Kantarci, Kejal , Nho, Kwangsik T. , Carrasquillo, Minerva M. , Saykin, Andrew J. , Ertekin‐Taner, Nilüfer

Mayo Clinic

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S8 | Pages: No page available

10.1002/alz70862_109896 Get It

Abstract Background Most existing biomarkers for Alzheimer’s disease (AD) inform on core AD pathologies in the central nervous system, namely amyloid, tau and neurodegeneration (ATN). However, molecular disease mechanisms underlying AD are complex and heterogeneous, highlighting the need for cost‐effective blood‐based biomarkers that reflect brain molecular changes in AD beyond ATN. Method Using peripheral blood transcriptome data from the Mayo Clinic Study of Aging(MCSA) and the Alzheimer's Disease Neuroimaging Initiative, we identified genes associated with AD or mild cognitive impairment (MCI) diagnosis, cognitive, and harmonized neuroimaging measures in two cohorts, followed by meta‐analysis. We identified consensus gene co‐expression modules in MCSA and ADNI using WGCNA and assessed the association between module eigengenes and aforementioned measures. Using seven bulk brain RNAseq cohorts, we confirmed the preservation of coexpression modules across blood and brain. Enrichment analyses of Gene Ontology (GO) terms and cell‐types were performed using significant and/or hub genes. The MCSA transcriptome was further deconvoluted to obtain cell‐type proportions and cell‐type specific expression. Result Blood transcriptome modules M5 and M8 are upregulated in AD/MCI and associate with worse cognition, whereas M1, M10, M13, M16, and M21 are downregulated in AD/MCI and associate with better cognition. M17 associates with more microhemorrhages. Cell‐type enrichment analysis revealed that M5 is enriched in basophils, monocytes, and neutrophils; M8 in monocytes and neutrophils; M13 in natural kills cells; M17 in megakaryocytes; M21 in B cells. GO analysis shows broad consistency with the cell‐type enrichment analysis. M1, 5, and 8 are preserved in the brain network modules. From these modules, we prioritized transcripts significantly associated with at least one AD‐related phenotype in both blood and brain. Cell‐type deconvolution analysis shows that prioritized transcripts in M1 associate with better cognition and higher metabolic activity in B cells. Conclusion We identified blood transcripts and modules associated with AD/MCI, cognition, or neuroimaging, with three preserved in brain networks. These three modules represent centrally linked peripheral molecular signatures that can reveal perturbed brain pathways and cell level transcriptional changes in AD/MCI. We aim to further investigate the prioritized transcripts in additional datasets to establish them as potential novel biomarkers and therapeutic targets.
Multi‐omics studies reveal convergent and divergent pathways in Alzheimer's and related disorders
Allen, Mariet , Oatman, Stephanie R., Wang, Xue, Reddy, Joseph S. , Nguyen, Thuy T. , Ertekin‐Taner, Nilüfer, Dickson, Dennis W. , Ertekin‐Taner, Nilüfer

Mayo Clinic

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S1 | Pages: No page available

10.1002/alz70855_096030 Get It

Abstract Background Alzheimer's disease (AD) is pathologically characterized by the presence of extracellular amyloid beta plaques and intracellular tau tangles. Related disorders share aspects of AD pathology including progressive supranuclear palsy (PSP), a tauopathy, and pathologic aging (PA) defined by presence of amyloid but not tau. We hypothesize that there are shared, and distinct, brain molecular changes associated with amyloid and tau protein levels in AD and related disorders and that identifying these will provide novel insights into disease pathogenesis. Methods We collected brain multiomics measures (genetic, transcriptomic, epigenomic, proteomic and metabolomic) from donors diagnosed with AD, PSP, PA and controls. Following quality control and normalization, omics measures were tested for association with disease diagnosis and amyloid and tau neuropathology using regression models adjusting for relevant covariates. Association with biochemical measures of core AD proteins were also assessed in a subset of AD cases. Gene sets were evaluated for enrichment of cellular pathways and cell type signatures. Results We found remarkably conserved transcriptomic changes associated with AD and PSP, and downregulation of myelination pathway genes in both diseases. Among PSP cases, we found divergent patterns of transcriptional associations with distinct tau lesions. In a cohort of AD cases, we found broad transcriptional and epigenetic dysregulation associated with levels of tau protein, but not amyloid beta. Conversely a genetic analysis implicated more variants associated with amyloid levels than tau. Conclusion Multi‐omics studies across various proteinopathies can identify convergent and divergent molecular signatures that are candidates for shared therapeutic targets and disease differentiating biomarkers.
Training in cell and gene therapy manufacturing: Unmet needs and arguments for graduate medical education
Wang, Yongping, McKenna, David H. , Spitzer, Thomas R. , Brunker, Patricia A. R. , DiGuardo, Margaret, Jacob, Eapen K., Nedelcu, Elena G , Fesnak, Andrew D. , Celluzzi, Christina M. , DiGuardo, Margaret

Mayo Clinic

Transfusion | December 23, 2025 | Volume: 66 | Issue: 1 | Pages: 259-265

10.1111/trf.70021 | PMID 41432689 Get It

Resolving Clinically Indeterminate Findings During Anal Cancer Surveillance with TTMV-HPV DNA
Kabarriti, R., Lloyd, Shane , Jabalee, James , Gay, Laurie M. , Slater, T. F., Guzman, Kayleen, Jacobs, Corbin D. , Inocencio, Sean, Lin, Ray , Nguyen, Cammie , MacEwan, Iain, Crawford, Alexandra H., Rutenberg, Michael, Singh, Jaswinder, Ross, Jennifer, Kim-Wang, Sophia Y., Matthiesen, Chance, Neff, Kasha, Liu, Gene-Fu, Juarez, Tiffany , Neff, Kasha , Jacobs, Corbin , Rutenberg, Michael , Neff, Kasha , Juarez, Tiffany M , Lloyd, Shane L , Slater, Tyler, Liauw, Stanley L.

Mayo Clinic

Cancers | December 23, 2025 | Volume: 18 | Issue: 1 | Pages: 35

10.3390/cancers18010035 | PMID 41514548 Get It

Background/Objectives: Surveillance for anal squamous cell carcinoma (ASCC) recurrence relies on clinical examination and imaging. Post-treatment edema, fibrosis, and inflammation can result in clinically indeterminate findings (CIFs) that delay diagnosis and increase patient and system burden. Circulating tumor tissue-modified viral (TTMV)-HPV DNA offers a biologically specific, noninvasive biomarker that may clarify equivocal assessments. Methods: In this multi-center retrospective study, 233 patients with HPV-associated ASCC were evaluated, including 185 with ≥1 post-treatment TTMV-HPV DNA test. CIFs were defined as exams or imaging results not definitively positive or negative for disease, and were paired with subsequent TTMV-HPV DNA tests. Concordance was defined by prespecified follow-up windows comparing TTMV-HPV DNA results with subsequent clinical outcomes. Results: Ninety patients (39%) experienced 214 CIFs, arising from exams (46%, 98) or imaging (54%, 116). Indeterminate rates by assessment were 7% for exams, 17% for imaging, and 1.3% for TTMV-HPV DNA testing. Overall, 52 CIF/TTMV-HPV DNA pairs were eligible for analysis, and TTMV-HPV DNA resolved disease status accurately for 48/52 (92%, 95% CI: 81.5–97.9). Negative tests predicted cancer-free status for 37/41 CIFs (90%), while 100% of positive tests (11/11) were concordant with clinically confirmed recurrence. In 73% of positive cases (8/11), TTMV-HPV DNA was the first indication of recurrence (median lead-time 29 days; IQR 25–147). Conclusions: TTMV-HPV DNA testing reliably clarifies clinically indeterminate findings during ASCC surveillance, demonstrating high accuracy (92%) and earlier detection of recurrence. These data support integration into post-treatment management to reduce diagnostic uncertainty and guide timely care.
Potential Role of Serum Cytokines and Chemokines as Biomarkers of Injury Severity and Functional Outcomes Following Pediatric Traumatic Brain Injury
Swaby, K., Skirvin, Alexander J. , Machado, Natalie Reichert, Bernal, Julia, Fuentes, Ana, Pringle, Charlene , Guthrie, Kourtney, Coto, Jennifer , Dhanashree, Rajderkar, Gober, Joslyn , Perez, Paula Karina, Solano, Juan P. , McCrea, Heather J. , Loor-Torres, Ricardo , Kaufman, Joyce, Alkhachroum, Ayham , O’Phelan, Kristine H., Kobeissy, Firas, Dietrich, W. Dalton, Vaccari, Juan Pablo de Rivero , Pareja, Jennifer C Munoz, Pareja, Jennifer C. Muñoz , Kobeissy, Firas , Swaby, Kathryn , Mateo Chavez, Maria, Fuentes, Ana , Pringle, Charlene P , Dhanashree, Rajderkar , McCrea, Heather J , Kobeissy, Firas , de Rivero Vaccari, Juan Pablo , Munoz Pareja, Jennifer C , Chavez, Maria Mateo , Keane, Robert W. , Wang, Kevin , Dietrich, W. Dalton

Mayo Clinic

Cells | December 22, 2025 | Volume: 15 | Issue: 1 | Pages: 19

10.3390/cells15010019 | PMID 41511302 Get It

Traumatic brain injury (TBI) is one of the leading causes of death and neurological disability worldwide. The search for biomarkers that indicate TBI severity and prognosis with greater accuracy is ongoing. This study aimed to evaluate the significance of several neuroinflammatory cytokines and chemokines, assessing their potential as biomarkers in pediatric TBI (pTBI). This was an exploratory analysis of inflammatory cytokines and chemokines measured in a subset of 26 children aged 0–18 years with TBI and 21 controls. TBI severity was determined by GCS. The functional outcome was measured via the GOS-E score at 6 weeks and 3, 6, 9, and 12 months post-injury. Serum samples were analyzed for ICAM-1, VCAM-1, SAA, CRP, IFN-g, IL-10, IL-12p70, IL-13, IL-1b, IL-2, IL-4, IL-6, IL-8, TNF-a, TNF-b, eotaxin, eotaxin-3, IP-10, MCP-1, MCP-4, MDC, MIP-1a, MIP-1b and TARC. Levels of IL-6, IL-10, IL-13, IL-16, MDC, and GM-CSF were increased, and IFN-γ, IL-5, IL-8, and eotaxin-3 were decreased at enrollment when compared with controls. Elevated IL-6 and IL-10 at enrollment were associated with severe TBI (AUC of 1, p = 0.0002 and p = <0.0001, respectively). IL-6, IL-10, IL-16, and TNF-β at enrollment and IL-5 at 24 h were elevated in children with unfavorable outcomes, with an AUC > 0.8, suggesting biomarker potential. Our data indicate that several cytokines and chemokines measured after TBI may aid in the assessment of pTBI severity and prognosis. IL-6, IL-10, and IL-16 may show potential as biomarkers for pTBI severity and outcomes.
Inflammation rewires the enteric nervous system through neurogenic monocyte recruitment
Kurapati, Sravya , Shin, Changsik , Szabo, Krisztina , Liu, Yu , Ashraf, Azree Zaffran, Koscsó, Balázs , Dash, Chinmayee , Kruckow, Katherine L. , Navarro, L Guerrero, Clark, Amanda M. , Saha, Monalee , Nagaraj, Sushma , Wang, Wenhui , Zhu, Jun , Thomson, Travis , Shulzhenko, Natalia , Morgun, Andrey , Pasricha, Pankaj J. , Peters, Lauren A., Bogunovic, Milena , Ashraf, Azree Z , Navarro, Leonardo E , Brown, Kevin , Thomson, Travis , Shulzhenko, Natalia , Morgun, Andrey , Baer, Christina E , Srinivasan, Shanthi , Kulkarni, Subhash , Pasricha, Pankaj Jay , Peters, Lauren A , Bogunovic, Milena , Clark, Amanda M. , Kulkarni, Subhash

Mayo Clinic

Journal of Experimental Medicine | December 20, 2025 | Volume: 223 | Issue: 4 | Pages: No page available

10.1084/jem.20251761 | PMID 41774078 Get It

Proper organization of the enteric nervous system (ENS) is critical for normal gastrointestinal (GI) physiology. Inflammatory bowel disease (IBD) disrupts key GI functions, including bowel motility. However, in many IBD patients, motility disorders persist even during remission, suggesting an irreversible ENS defect secondary to IBD. Here, we show that postinflammatory GI motility dysfunction arises from structural remodeling of the ENS, driven by a combination of neuronal loss and neurogenesis. During mucosal inflammation, enteric neurons upregulate CCL2 expression, facilitating the recruitment of monocytes into the myenteric plexus within the intestinal muscle. Monocyte-derived macrophages infiltrate the myenteric ganglia, contributing to excessive ENS remodeling and postinflammatory motility dysfunction. This neuroimmune axis is counterbalanced by a hypoxia-induced stress response in enteric neurons mediated by HIF1α. Enhancing the neuron-intrinsic hypoxia pathway limits ENS remodeling and preserves motility. In summary, this study presents a mechanistic model of postinflammatory GI motility dysfunction and proposes a therapeutic strategy to maintain ENS integrity and function during inflammation.
Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with ≥5% blasts: An International TP53 Investigators Network (iTiN) study
Yasin, Irfan , Stengel, Anna , Shao, Haipeng , Kaur, Amandeep , Patwardhan, Pranav Pramod , Bailey, Nathanael G. , Inamdar, Kedar , Patel, Anand , Pandiri, M, Sojitra, Payal , Tariq, Hamza , Pan, Zenggang , Wiredja, Danica , Tjota, Melissa Y. , Segal, Jeremy , Chang, Hong , Sallman, David A. , Tefferi, Ayalew , Badar, Talha , Perry, Anamarija M. , Haferlach, Claudia, Patwardhan, Pranav P , Tefferi, Ayalew , Badar, Talha , Venkataraman, Girish , Patel, Anand , Shao, Haipeng, Mason, Emily F. , Ghosh, Sharmila , Zhang, Jingjing , Wang, Peng , Arber, Daniel A. , Haferlach, Claudia , Lager, Angela M.

Mayo Clinic

Cancer | December 19, 2025 | Volume: 132 | Issue: 1 | Pages: No page available

10.1002/cncr.70210 | PMID 41417597 Get It

ABSTRACT Background Isolated chromosome 5/5q losses (–5/5q) without TP53 mutations are associated with favorable outcomes in myeloid neoplasms (MN) with <5% blasts. However, the clinical implication of concurrent −5/5q and TP53 aberrations in MN with ≥5% blasts is poorly understood. Methods Patients with TP53 ‐mutated MN carrying ≥5% blasts assessing the prognostic impact of ‐5/5q on 24‐month overall survival (OS24) were examined. Results Of 587 patients, 515 (88%) exhibited −5/5q overwhelmingly in the context of a complex karyotype (98.3% vs. 61.1% complex karyotype without −5/5q; p < .0001) and multihit TP53 allelic state (88.3% vs. 56.9%; p < .0001). Proportions of patients with blasts ≥20% were comparable between groups with and without −5/5q; p = 0.26. Notably, patients with −5/5q exhibited significantly fewer coalterations; p < .0001. Looking at outcomes, presence of −5/5q was associated with shorter median 24‐month overall survival (7.8 months vs. 11.2 months; p Log‐rank = .012), an effect restricted to subgroups with blasts <20% ( p = .039; N = 163), absent −7/7q ( p = .007; N = 225), or WHO5‐defined single hit allelic state ( p = 0.030; N = 91). Importantly, −5/5q retained independent adverse prognostic significance regardless of TP53 allelic state in a multivariable model. Furthermore, among the subset of 75 (13%) patients undergoing allogeneic stem cell transplantation, −5/5q predicted significantly shorter median 5‐year posttransplant survival (16.2 months vs. median not reached; p Log‐rank = .009). Conclusions These findings emphasize the independent prognostic relevance of chromosome 5/5q losses underscoring the clinical relevance of cytogenetic testing for −5/5q even in this high‐risk cohort.
Real-world evaluation of inter-consensus agreement on the Murad tool for appraising the methodological quality of case reports and case series
Hegazi, Moustafa , Saadi, Samer , Allababidi, Adel Kabbara , Farah, Magdoleen H. , Abusalih, Mohamed , Basha, Ayla Shamsi , Hasan, Bashar , Rajjo, Tamim , Murad, M. Hassan , Kabbara Allababidi, Adel , Shamsi Basha, Ayla, Wang, Zhen , Murad, M Hassan , Saadi, Samer , Farah, Magdoleen H , Hasan, Bashar , Abusalih, Mohamed , Rajjo, Tamim I , Wang, Zhen

Mayo Clinic

JBI Evidence Synthesis | December 19, 2025 | Volume: 24 | Issue: 3 | Pages: 444-458

10.11124/jbies-25-00225 | PMID 41414955 Get It

Objective: The objective of this investigation was to evaluate the agreement rate on judgments made using the Murad tool by different systematic review teams. Introduction: Evaluating the methodological quality of case reports and case series is challenging but some tools do exist for this purpose. We leveraged the presence of studies that have been evaluated by different systematic review teams to assess the inter-consensus agreement among different teams on Murad tool domains. Methods: Using a back-citation method, we identified systematic reviews that used the Murad tool and retrieved all the included primary studies. We selected studies that were assessed by more than 1 systematic review team. We calculated observed agreement and Gwet’s agreement coefficient on judgments made about each signaling question. Results: We identified 982 systematic reviews that cited the Murad tool and collectively cited 59,080 references. The final data comprised of 81 duplicated case reports and series assessed by more than 1 systematic review team. Overall, the signaling questions had very high observed agreement with 5 of the 8 questions having agreement over 75%. The signaling questions with the highest agreement addressed the adequacy of the ascertainment of the exposure (coefficient 0.959), ascertainment of the outcome (coefficient 0.829), presence of a dose-response gradient (perfect agreement), and clarity of reporting (coefficient 0.755). Conclusion: The current study demonstrates overall high agreement among different systematic review teams that used the Murad tool for appraisal of the same case series and case reports. Leveraging duplicated studies across systematic reviews is a feasible way to retrospectively assess the reliability of the tool.
Cortical asymmetry in autosomal dominant Alzheimer’s disease progression
Pérez-Millan, Agnès , Falgàs, Neus , Borrego-Écija, Sergi, Antonell, Anna, Fernández-Villullas, Guadalupe, Esteller-Gauxax, Diana, Tort-Merino, Adrià, Bargalló, Núria, Balasa, Mircea, Lladó, Albert, Chrem, Patricio, Day, Gregory S. , Devenney, Emma , Huey, Edward D. , Ikeuchi, Takeshi, Jucker, Mathias, Roh, Jee Hoon , Vitali, Paolo , Ortíz, Ana Luisa Sosa, Llibre-Guerra, Jorge J, Gordon, Brian A., Sánchez-Valle, Raquel, (DIAN), The Dominantly Inherited Alzheimer Network, Daniels, Alisha , Courtney, Laura, Ziegemeier, Angela, Skrbec, Karina, Hellm, Cortaiga, Martin, Mariana , Ziegemeier, Ellen , Bartzel, Jamie, Xiong, Chengie , Xu, Xiong, Lu, Ruijin, Li, Yan , Nie, Yuzheng , Gremminger, Emily, Perrin, Richard J. , Franklin, Erin , Ibanez, Laura, Jerome, Gina, Stauber, Jennifer, Baker, Bryce, Minton, Matthew, Cruchaga, Carlos C, Goate, Alison M, Renton, Alan E, Picarello, Danielle M. , Benzinger, Tammie L S, Hornbeck, Russ C. , Chen, Allison, Chen, Charles D., Flores, Shaney, Joseph-Mathurin, Nelly, Jackson, Kelley, Keefe, Sarah , Koudelis, Deborah, Massoumzadeh, Parinaz , Nicklaus, Joyce , Pulizos, Christine, Wang, Qing, Sabaredzovic, Edita, Scott, Jalen , Simmons, Ashlee, Rizzo, Jacqueline, Vlassenko, Andrei G. , Wang, Yong, Hassenstab, Jason, Smith, Jennifer, Stout, Sarah, Marsh, Jacob, Morris, John C, Barthélemy, Nicolas R. , Xu, Jinbin , Ikonomović, Snežana, Graff-Radford, Neill R, Farlow, Martin R. , Chhatwal, Jasmeer P. , Maa, Courtney, Ishiguro, Takanobu , Ishii, Kenji, Senda, Michio, Salloway, Stephen , Bechara, Jacob A, Martins, Ralph, Fox, Nick C, Ryan, Natalie S. , Laske, Christoph , Timofejavaite, Reda, Kuder-Buletta, Elke, Graber-Sultan, Susanne, Obermueller, Ulrike, Xiong, Chengjie , Rödenbeck, Yvonne, Vӧglein, Jonathan, Méndez, Patricio Chrem, Vazquez, Silvia, Leon, Yudy Milena, Ramirez, Laura, Baena, Ana , Bocanegra, Yamile , Levey, Allan, Johnson, Erik C B, Seyfried, Nicholas T. , Ringman, John M. , Fagan, Anne M. , Mori, Hiroshi, Lopera, Francisco , Goate, Alison , Hassenstab, Jason , Borrego‐Écija, Sergi , Pérez‐Millan, Agnès , Ikeuchi, T , Vöglein, Jonathan , Roh, Jee Hoon , Vitali, Paolo , Gordon, Brian A , Bateman, Randall J , Sánchez-Valle, Raquel , Day, Gregory S , Xiong, Chengjie , Hassenstab, Jason , Borrego-Écija, Sergi , Goate, Alison M , Bosch, Beatríz , Antonell, Anna, Fernández‐Villullas, Guadalupe , Esteller, Diana , Tort‐Merino, Adrià , Balasa, Mircea , Lladó, Albert , Aguillon, David , Ikeuchi, Takeshi , Jucker, Mathias , Kasuga, Kensaku , Vöglein, Jonathan , Llibre‐Guerra, Jorge J. , Gordon, Brian A. , McDade, Eric , Bateman, Randall J. , Sánchez‐Valle, Raquel , Supnet, Charlene , Lu, Ruijin, Wang, Guoqiao , Ibanez, Laura , Cruchaga, Carlos , Fulton‐Howard, Brian , Banks, Jessica N , Flores, Shaney , Goyal, Manu S. , Hobbs, Diana A. , Joseph‐Mathurin, Nelly , McCullough, Austin , McKay, Nicole S. , Wang, Yong , Smith, Jennifer, Stout, Sarah H., Aschenbrenner, Andrew J. , Karch, Celeste M. , Marsh, Jacob A. , Holtzman, David M. , Berman, Sarah , Graff‐Radford, Neill R. , Senda, Michio , Niimi, Yoshiki , Schofield, Peter R. , Brooks, William S. , Bechara, Jacob , Cash, David M. , Laske, Christoph , Fougère, Christian la , Reischl, Gerald , Lee, Jae Hong , Allegri, Ricardo , Surace, Ezequiel , Vazquez, Silvia, Ramírez, Laura, Serna, Laura, Johnson, Erik C. B. , Masters, Colin L. , Noble, James M. , Lopera, Francisco Javier

Mayo Clinic

Brain Communications | December 18, 2025 | Volume: 8 | Issue: 1 | Pages: No page available

10.1093/braincomms/fcaf488 | PMID 41523185 Get It

Abstract The cortical asymmetry index evaluates the cortical thickness asymmetry between hemispheres. We investigated cortical asymmetry index in asymptomatic and symptomatic mutation carriers of autosomal dominant Alzheimer’s disease to explore the brain asymmetry within the Alzheimer’s disease continuum. Sixty baseline T1-weighted MRI scans were obtained from the Clinic Barcelona cohort. Baseline and longitudinal MRI data from 564 participants within the dominantly inherited Alzheimer network observational study were used as an independent, confirmatory cohort. Cerebrospinal fluid and plasma neurofilament light chain levels were included when available. Cortical thickness was calculated using Freesurfer and cortical asymmetry index was calculated via an open-source pipeline. Cross-sectional analyses examined cortical asymmetry index differences based on clinical classification and APOE ε4 status, adjusting for age, sex and estimated years from onset, while correlations were assessed with age, estimated years from onset, mini-mental state examination scores, and neurofilament light. Longitudinal cortical asymmetry index evolution was modelled using generalized additive models in the dominantly inherited Alzheimer network observational study cohort, incorporating age, sex, and the interaction between group and estimated years from onset. The cortical asymmetry index successfully distinguished asymptomatic mutation carrier and symptomatic mutation carriers from healthy controls in the Clinic Barcelona cohort and symptomatic mutation carriers from controls in dominantly inherited Alzheimer network observational study. Higher cortical asymmetry index in mutation carriers (asymptomatic mutation carrier and symptomatic mutation carriers combined) and in symptomatic mutation carriers were associated with higher plasma neurofilament light levels, a closer proximity to symptom onset, and lower mini-mental state examination in the Clinic Barcelona cohort. In the dominantly inherited Alzheimer network observational study cohort, mutation carriers exhibited increased cortical asymmetry index compared to controls and correlated with elevated neurofilament light (plasma and Cerebrospinal fluid), lower mini-mental state examination, and a closer proximity to symptom onset. APOE3/3 carriers showed greater asymmetry than other APOE genotypes and significant cortical asymmetry index differences between asymptomatic mutation carrier and symptomatic mutation carriers. Longitudinally, cortical asymmetry index increased over time significantly in symptomatic mutation carriers. These findings underscore brain asymmetry as a potential biomarker for early Alzheimer’s disease progression in autosomal dominant Alzheimer’s disease, with implications for detection and monitoring tracking disease-related neuroanatomical changes.
Immuno‐Regulation of Brain Region‐Specific Organoids Containing Isogenic Microglia‐Like Cells
Ene, Justice , Lü, Wenyan, Syed, Falak, Ren, Yi , Kanekiyo, Takahisa , Li, Yan , Li, Yan , Liu, Chang , Syed, Falak, Sun, Li , Raulin, Ana‐Caroline , Wang, Xueju Sophie

Mayo Clinic

Advanced Healthcare Materials | December 18, 2025 | Volume: 15 | Issue: 10 | Pages: No page available

10.1002/adhm.202503579 | PMID 41408986 Get It

ABSTRACT Most brain organoids derived from human induced pluripotent stem cells (iPSCs) lack microglia and thus immune function. Microglia‐like cells (MGCs) can be differentiated from iPSCs, while the characteristics of isogenic MGC‐containing brain organoids in modeling neurodegeneration and cell‐cell communications have not been well investigated. In this study, iPSC‐derived MGCs are co‐cultured with isogenic forebrain cortical organoids (iFCo), which are stimulated with extracellular vesicles (EVs) of brain organoids differentiated from Alzheimer's disease (AD) patient‐derived iPSCs ( APOE ε4/ε4 and presenilin 1). The AD EV‐stimulated co‐culture organoids are treated with EVs from healthy MGCs or co‐culture. Differential responses of the co‐cultured organoids and the MGCs to AD EVs are demonstrated. The co‐cultured organoids mitigated pro‐inflammatory gene expressions. EVs from healthy MGCs or co‐culture reduced the expression of IL‐12β , iNOS , TREM2 , and CASS4 , which are associated with neural inflammation and degeneration, as well as showed regulation on genes involved in microglial activation and carbon metabolism. AD EV cargo analysis by proteomics and microRNA‐sequencing revealed APOE and APP proteins and microRNAs regulated pathways such as mitophagy. This study paves the way for understanding the role of microglia and brain organoids in modeling neural degeneration and the development of EV‐based cell‐free therapeutics for AD treatment.